EP0542846A1 - Piperidines a substitution n-hydrocarbyle en position 4, leur preparation et leur utilisation comme agents de blocage du calcium - Google Patents

Piperidines a substitution n-hydrocarbyle en position 4, leur preparation et leur utilisation comme agents de blocage du calcium

Info

Publication number
EP0542846A1
EP0542846A1 EP91914558A EP91914558A EP0542846A1 EP 0542846 A1 EP0542846 A1 EP 0542846A1 EP 91914558 A EP91914558 A EP 91914558A EP 91914558 A EP91914558 A EP 91914558A EP 0542846 A1 EP0542846 A1 EP 0542846A1
Authority
EP
European Patent Office
Prior art keywords
ethyl
compound
pentylpiperidine
phenyl
title compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91914558A
Other languages
German (de)
English (en)
Inventor
Thomas Henry Smithkline Beecham Brown
David Gwynn Smithkline Beecham Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909017224A external-priority patent/GB9017224D0/en
Priority claimed from GB919107757A external-priority patent/GB9107757D0/en
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Publication of EP0542846A1 publication Critical patent/EP0542846A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Definitions

  • the present invention relates to 4-substituted piperidine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
  • the present invention therefore provides, in a first aspect, compounds of structure (I);
  • R is C 1-8 alkyl (phenyl)p, C 2-8 alkenyl (phenyl)p,
  • p is 0 to 2 ;
  • n 0 to 6 ;
  • A is a bond, oxygen, sulphur or NR 1 ;
  • R 1 is hydrogen, C 1-8 alkyl or phenylC 1-4 alkyl
  • n 0 to 3;
  • Ar is aryl or heteroaryl, each of which may be
  • R is C 1-8 alkyl(phenyl)p, C 2-8 alkenyl-(phenyl)p, C 2-8 alkynyl(phenyl)p, C 3-8 cycloalkyl or
  • alkylcycloalkyl, alkylphenyl, alkenylphenyl and alkynylphenyl groups are linked to the piperidine nitrogen atom via the alkyl, alkenyl and alkynyl moieties respectively.
  • R is C 1-8 galkyl(phenyl)p in which p is 0 or 1, i.e. C 1-8 alkyl, such as n-pentyl, or phenylC 1-8 alkyl such as phenylpropyl, or R is C 2-8 alkenyl(phenyl)p where p is 1, such as cinnamyl.
  • n is 0 to 6; preferably n is 0 to 3; most preferably n is 2 or 3.
  • n is 0 to 3; preferably m is 0 or 1;
  • A is a bond, oxygen, sulphur or NR 1 ;
  • A is oxygen or sulphur; most preferably A is oxygen.
  • A is oxygen
  • n is preferably 2 and m is preferably 0.
  • Ar is optionally substituted aryl or heteroaryl; preferably Ar is optionally substituted aryl.
  • Suitable aryl groups include, for example,
  • unsaturated monocyclic and unsaturated or partially saturated bicyclic ring systems of up to 10 carbon atoms, such as, for example, phenyl, naphthyl and
  • Suitable substituted phenyl rings include, for example, phenyl rings substituted by a C 1-2 alkylenedioxy group such as a 3,4-methylenedioxy group or by 1 to 3 substituents selected from halogen, C 1-4 alkoxy,
  • phenyl can be H or C 1-4 alkyl), OCF 3 , C 1-6 alkyl, trifluoromethyl, CN, optionally substituted phenyl, optionally substituted phenylC 1-4 alkyl and optionally substituted phenylC 1-4 alkoxy.
  • Suitable optionally substituted phenylC 1-4 alkyl groups include, for example benzyl.
  • Suitable optionally substituted phenylC 1-4 alkoxy groups include, for example
  • phenylC 1-4 alkoxy groups include for example halogen, C 1-4 alkyl, C 1-4 alkoxy, nitro and trifluoromethyl groups.
  • Suitable heteroaryl rings include, for example, unsaturated monocyclic and unsaturated or partially saturated bicyclic ring systems of up to 10 carbon atoms containing lat "least one heteroatom, such as pyridyl, thienyl, quinolinyl, tetrahydroquxnolxnyl and imidazolyl rings.
  • the heteroaryl ring can be linked to the
  • Suitable substituents for said heteroaryl rings include, for example, 1 to 3 substituents selected from halogen, C 1-4 alkyl and C 1-4 alkoxy.
  • Alkyl groups present in the compounds of structure (I), alone or as part of another group, can be straight or branched. It will be appreciated that for use in medicine a salt of a compound (I) should be pharmaceutically
  • salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically acceptable inorganic or organic acid addition salts.
  • Other nonpharmaceutically acceptable salts may be used for example as intermediates and are included within the scope of this invention.
  • Particular compounds of the invention include : 4-[2-(4-trifluoromethylphenoxy)ethyl]-1-pentylpiperidine oxalate,
  • structure (I) may contain one or more asymmetric
  • the compounds of the present invention can be prepared by processes analogous to those known in the art.
  • the present invention therefore provides in a further aspect, a process for the preparation of a compound of structure (I) which comprises:
  • R and n are as described for structure (I) and A 1 is O, S or NR 1 , with a compound of structure
  • n and R are as described for structure (I) and L 1 is a group displaceable by a nucleophile, with a compound of structure HA 1 (CH 2 ) m Ar where m and Ar
  • R 5 is C 1-7 alkyl (phenyl)p, C 2-7 alkenyl(phenyl)p, C 2-7 alkynyl(phenyl)p or C 1-7 alkylC 3-8 cycloalkyl;
  • R, A, Ar m and n are as hereinbefore defined and X ⁇ is a counter ion; and optionally thereafter forming a salt.
  • fluoro-substituted aryl F-Ar is employed in process (a), the reaction is effected in the presence of a strong base such as sodium hydride, and in an inert organic solvent such as dimethyl formamide.
  • a strong base such as sodium hydride
  • an inert organic solvent such as dimethyl formamide.
  • the aryl group is substituted by an activating group such as CF 3 or NO 2 .
  • the reaction between a compound of structure (III) and a compound of structure HA 1 (CH 2 ) m Ar can take
  • the leaving group L 1 may be for example a halogen atom or a sulphonyloxy group eg. methanesulphonyloxy or p-toluenesulphonyloxy.
  • the reaction may be effected in the presence or absence of solvent at a temperature in the range 0 to 200°C
  • the reduction of a compound of structure (IV) can be effected by methods known in the art, for example using a reducing agent such as lithium aluminium hydride.
  • a compound of structure (IV) can be prepared (for example as described below) and reduced in a
  • reaction of a compound of structure (VI) with RL 2 according to process (e) may be effected in
  • the leaving group L 2 may be for example a halide such as bromide or chloride, an acyloxy group such as acetoxy or chloroacetoxy or a sulphonyloxy group such as methanesulphonyloxy or p-toluene sulphonyloxy.
  • L 2 is a halide
  • reaction is preferably carried out in the presence of a weak base such as potassium carbonate, and when L 2 is sulphonyloxy, a strong base such as sodium hydride or potassium t-butoxide may be employed.
  • a weak base such as potassium carbonate
  • a strong base such as sodium hydride or potassium t-butoxide
  • Reduction of a compound of formula (VII) may be effected using standard reducing agents such as lithium aluminium hydride.
  • Reduction of a compound of formula (VIII) may be effected for example by hydrogenation, using a noble metal catalyst such as platinum, palladium or platinum oxide, suitably in a solvent such as an alcohol eg.
  • a noble metal catalyst such as platinum, palladium or platinum oxide
  • the compounds of structure (II) can be prepared from the corresponding compounds in which R is hydrogen, by alkylation under standard conditions.
  • compounds of structure (II) in which R is n-pentyl can be prepared from the corresponding precursor in which R is hydrogen by reaction with an n-pentylhalide such as n-pentyl bromide in a suitable solvent, such as methyl ethyl ketone, or a C 1-4 alkanol such as ethanol, in the presence of a base, such as potassium carbonate, or dimethylformamide in the presence of an iodoalkane.
  • a suitable solvent such as methyl ethyl ketone
  • a C 1-4 alkanol such as ethanol
  • compounds of structure (II) in which A 1 is oxygen can be prepared by reduction of a compound of structure (IX): (IX)
  • halogen atom, or a mesyloxy or tosyloxy group can be prepared from the corresponding alcohol in conventional manner.
  • Compounds of structure (IV) wherein R 4 is a group can be prepared by
  • R 4 represents -(CH 2 ) n-1 CO 2 H or an activated
  • the carboxylic acid may itself be prepared for example by oxidation of the corresponding alcohol, ie. a compound of structure (II) wherein A 1 is oxygen.
  • Compounds of structure (V) may be prepared in analogous manner to compounds of structure (III); where necessary the chain length may be increased using methods well known in the art.
  • Suitable protecting groups include aralkyl groups such as benzyl, diphenylmethyl or triphenylmethyl and acyl groups such as acetyl, trifluoroacetyl, benzoyl,
  • benzyloxycarbonyl methoxycarbonyl, ethoxycarbonyl, or benzyloxycarbonyl.
  • An aralkyl group such as benzyl may be cleaved by
  • a compound of formula (VII) may be prepared by reaction of a compound of formula (VI) with an
  • appropriate acid derivative for example an acid chloride, or anhydride.
  • a compound of structure (VIII) may be prepared using the general methods described in processes (a) to (e) above.
  • compounds of structure (VIII) wherein A represents a bond may be prepared from 4-methyl pyridine (picoline) by reaction with a compound of formula L(CH 2 )q Ar wherein L and Ar are as hereinbefore defined and q is (m+n-1), in the presence of a strong base such as sodium amide in liquid ammonia or an alkyl lithium.
  • the resulting substituted pyridine is then reacted with a compound RL 2 , as hereinbefore defined, to give a quaternary pyridinium compound of formula (VIII).
  • Reduction of this compound according to process (g) provides a convenient method of preparing compounds of structure (I) wherein A represents a bond.
  • the compounds of the invention have been found to exhibit high calcium influx blocking activity and as such are expected to be of use in therapy in treating
  • the compounds are expected to be of use in the treatment of anoxia, ischaemia including for example stroke, migraine, epilepsy, traumatic head injury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, and drug addiction withdrawal such as ethanol addiction withdrawal.
  • a method of treatment of conditions or diseases caused or exacerbated by the accumulation of calcium in the brain cells of mammals which comprises administering to a subject in need thereof an effective amount of a compound of structure (I) or a
  • the present invention also provides a method of treatment of anoxia, ischaemia including for example stroke, migraine, epilepsy, traumatic head injury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, and drug addiction withdrawal such as ethanol addiction withdrawal, which comprises administering to a subject in need thereof, an effective amount of a compound of structure (I) or a pharmaceutically acceptable salt thereof.
  • the invention also provides the use of a compound of structure (I) or a pharmaceutically
  • the compounds of the present invention are usually administered in a standard
  • compositions comprising a compound of structure (I) or a pharmaceutically acceptable salt thereof and a
  • pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
  • a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
  • a composition in the form of a tablet can be
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures.
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable
  • compositions for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • compositions consist of a solution or suspension of the compound or pharmaceutically acceptabl salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol,
  • the solution can be
  • composition is in unit dose form such as a tablet or capsule.
  • dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral
  • administration contains preferably from 0.1 to 60 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
  • the daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, eg. 5 to 200 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 60 mg, eg. 1 to 40 mg of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
  • the compounds of the invention may be administered by continuous intravenous infusion, preferably at a dose of up to 100mg per day.
  • the compounds will be administered for a period of continuous therapy, for example for a week or more.
  • the pipette (internal solution) contained in mM: CsCl, 130; HEPES, 10; EGTA, 10; MgCl 2 , 4; ATP, 2;
  • Peak voltage gated Ca 2+ channel currents of up to 10 nA from dorsal root ganglion neurons were recorded using 10 mM Ba 2+ as charge carrier. Currents were evoked from a holding potential of -80 mV to a test potential of 0 or +10 mV every 15 seconds. This test potential was at the peak of the current voltage
  • Example 9 did not show any adverse toxicological effects when administered to rats at a dose of 10 mg/kg, i.v. PHARMACEUTICAL FORMULATIONS
  • Compound of structure (I) 0.1 - 60 mg sodium hydroxide or hydrochloric acid to pH ca 7 polyethylene glycol 0 - 2.5 ml alcohol 0 - 2.5 ml water to 5 ml
  • a toxicity adjusting agent eg. sodium chloride, dextrose or mannitol may also be added.
  • the title compound was prepared in a similar manner to example 1 from 4-hydroxy-1-pentylpiperidine (2.0g), sesamol (1.66g), triphenylphosphine (3.15g) and diethyl azodicarboxylate (2.09g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate (0.65g), m.p. 164°C.
  • the title compound was prepared in a similar manner to example 1 from 4-(2-hydroxyethyl)-1-(3-phenylpropyl)piperidine (2.47g), 4-fluorophenol (1.12g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from methanol/ethyl acetate (0.65g), m.p. 111-113°C.
  • the title compound was prepared in a similar manner to example 1 from 4-(2-hydroxyethyl)-1-heptylpiperidine (2.27g), sesamol (1.38g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from methanol/ethyl acetate (0.65g), m.p. 129-231°C.
  • Example 42 4- [2- (4-Fluorothiophenoxy) ethyl] -1-pentylpiperidine hydrochloride
  • the title compound was prepared in a similar manner to example 1 from 4-(2-hydroxyethyl)-1-pentylpiperidine (2.00g), 4-fluorothiophenol (1.28g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from ethyl acetate to give the title compound as white plate crystals (0.33g), m.p.164165°C. Found: C, 62.41; H, 8.47; N, 4.09; Cl, 10.17%
  • triphenylphosphine (1.96g) and diethyl azodicarboxylate
  • the title compound was prepared in a similar manner to example 1 from 4-(2-hydroxyethyl)-1-pentylpiperidine (1.5g), 4-isopropylphenol (1.02g), triphenylphosphine (1.96g) and diethyl azodicarboxylate (1.19ml). Treating the product with hydrogen chloride gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (1.21g), m.p.185-187°C.
  • the title compound was prepared in a similar manner to example 1 from 4-(2-hydroxyexhyl)-1-pentylpiperidine (1.5g), 3-isopropylphenol (1.02g), triphenylphosphine (1.96g) and diethyl azodicarboxylate (1.19ml). Treating the product with hydrogen chloride gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (0.5g), m.p.166-168°C.
  • the title compound was prepared in a similar manner to example 1 from 4-(2-hydroxyethyl)-1-pentylpiperidine (1.5g), 3-tert-butylphenol (1.127g), triphenylphosphine (1.96g) and diethyl azodicarboxylate (1.19g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (0.80g), m.p.171-173°C.
  • the title compound was prepared in a similar manner to example 1 from 4-(2-hydroxyethyl)-1-pentylpiperidine (2.0g), 3,5-dichlorophenol (1.63g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (l.lg), m.p.168-170°C.
  • the title compound was prepared in a similar manner to example 1 from 4- (2-hydroxyethyl) -1-heptylpiperidine (2.27g) , 3, 4 dichlorophenol (1. 63g) , triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (0.7g), m.p.138-139°C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composés de la structure (I) dans laquelle R représente C1-8 alkyle(phényle)p, C2-8 alkényle(phényle)p, C2-8 alcényle(phényle)p, C3-8 cycloalkyle ou C1-8 alkyle C3-8 cycloalkyle; p est compris entre 0 et 2; n est compris entre 0 et 6; A représente une liaison, oxygène, soufre ou NR1; R1 représente hydrogène, C1-8 alkyle ou phényle C1-4 alkyle; m est compris entre 0 et 3; et Ar représente aryle ou hétéroaryle, chacun d'entre eux pouvant être éventuelement substitués, ainsi que leurs sels; procédés de préparation desdits composés (I), compositions pharmaceutiques qui les contiennent et leur utilisation thérapeutique, notamment comme agents de blocage du calcium.
EP91914558A 1990-08-06 1991-08-05 Piperidines a substitution n-hydrocarbyle en position 4, leur preparation et leur utilisation comme agents de blocage du calcium Withdrawn EP0542846A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909017224A GB9017224D0 (en) 1990-08-06 1990-08-06 Compounds
GB9017224 1990-08-06
GB9107757 1991-04-12
GB919107757A GB9107757D0 (en) 1991-04-12 1991-04-12 Compounds

Publications (1)

Publication Number Publication Date
EP0542846A1 true EP0542846A1 (fr) 1993-05-26

Family

ID=26297463

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91914558A Withdrawn EP0542846A1 (fr) 1990-08-06 1991-08-05 Piperidines a substitution n-hydrocarbyle en position 4, leur preparation et leur utilisation comme agents de blocage du calcium

Country Status (15)

Country Link
EP (1) EP0542846A1 (fr)
JP (1) JPH06500093A (fr)
KR (1) KR930701402A (fr)
CN (1) CN1061963A (fr)
AP (1) AP279A (fr)
AU (1) AU8327191A (fr)
CA (1) CA2088491A1 (fr)
IE (1) IE912759A1 (fr)
IL (1) IL99073A0 (fr)
MA (1) MA22250A1 (fr)
MX (1) MX9100513A (fr)
NZ (1) NZ239268A (fr)
PT (1) PT98574A (fr)
TW (1) TW267164B (fr)
WO (1) WO1992002502A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534525B1 (en) 1995-12-22 2003-03-18 Warner-Lambert & Company 2-substituted piperidine analogs and their use as subtype-selective NMDA receptor antagonists

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109002A (en) * 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
DE69229674T2 (de) * 1991-09-12 2000-04-06 Smithkline Beecham Plc 5-ht4 rezeptor antagonisten
AU3364493A (en) * 1992-01-28 1993-09-01 Smithkline Beecham Plc Compounds as calcium channel antagonists
NO300539B1 (no) 1992-11-30 1997-06-16 Sankyo Co alfa,omega-diarylalkanderivater, med terapeutisk aktivitet for behandling og forhindring av sirkulasjonssykdommer og psykoser, og farmasöytiske preparater inneholdende disse derivater
GB9226111D0 (en) * 1992-12-15 1993-02-10 Smithkline Beecham Plc Madicaments
GB9314973D0 (en) * 1993-07-20 1993-09-01 Smithkline Beecham Plc Medicaments
GB9319534D0 (en) * 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
WO1995024390A1 (fr) * 1994-03-11 1995-09-14 Smithkline Beecham Plc Nouvelles piperidines substituees par phenyl(-alkyl/alkoxy)-1-aminoalkyle et pyrolidines utilisees comme antagonistes des canaux calciques
GB9411052D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Medicaments
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
AU4304596A (en) * 1994-12-21 1996-07-10 Neurosearch A/S A process for the preparation of substituted 4-ethyl-piperidines and an intermediate for the preparation of same
AUPN037195A0 (en) * 1995-01-03 1995-01-27 Australian Nuclear Science & Technology Organisation Piperidine-based sigma receptor ligands
ATE256110T1 (de) * 1995-09-15 2003-12-15 Neurosearch As Piperindinverbindungen als calcium-kanal-blocker
FR2742051B1 (fr) * 1995-12-06 1998-02-06 Synthelabo Utilisation de composes ayant une affinite pour le site de liaison du (3h)ifenprodil pour la fabrication de medicaments utiles dans la prevention et le traitement des neuropathies
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
US5843983A (en) * 1996-02-15 1998-12-01 Sankyo Company, Limited Diphenylethane compounds containing a saturated heterocyclic group, their preparation, and their therapeutic use
AU713527B2 (en) * 1996-08-12 1999-12-02 Merck & Co., Inc. Thrombin inhibitors
WO1999043658A1 (fr) 1998-02-27 1999-09-02 Warner-Lambert Company Agents d'aniline heterocyclique substituee bloquant les canaux de calcium
US6166052A (en) 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
JP4932994B2 (ja) * 1999-04-07 2012-05-16 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン 抗癌性カルシウムチャンネル遮断薬
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
US7294637B2 (en) 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
US7517892B2 (en) 2000-09-11 2009-04-14 Sepracor Inc. Ligands for monoamine receptors and transporters, and methods of use thereof
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
AR042628A1 (es) * 2002-12-20 2005-06-29 Astrazeneca Ab Derivados de piperidina como moduladores del receptor ccr5
SE0203828D0 (sv) * 2002-12-20 2002-12-20 Astrazeneca Ab Chemical compounds
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
EP1641775B1 (fr) 2003-07-03 2009-02-18 Euro-Celtique S.A. Derives de 2-pyridine alkyne servant au traitement de la douleur
TW200610761A (en) 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
SE0401656D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
FR2872416B1 (fr) * 2004-07-01 2006-09-22 Oreal Utilisation de derives de piperidine pour lutter contre les rides
NZ567629A (en) * 2005-09-23 2011-08-26 Ms Science Corp Piperazine derivatives useful in the treatment of discorders of the central nervous system
EP2340835A1 (fr) 2006-01-27 2011-07-06 M's Science Corporation Dérivés de pipéridine et de pipérazine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031221A (en) * 1974-06-17 1977-06-21 American Hoechst Corporation Method of treating pain and hypertension
DE3170628D1 (en) * 1981-10-15 1985-06-27 Synthelabo Piperidine derivatives, their preparation and use in medicine
US4546105A (en) * 1984-09-04 1985-10-08 Hoechst-Roussel Pharmaceuticals Inc. Pyrrolylaminopiperidines, compositions thereof and methods of use
DE3441929A1 (de) * 1984-11-16 1986-05-28 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von substituierten piperidinen
DE3529994A1 (de) * 1985-08-22 1987-02-26 Hoechst Ag Indolinonderivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
MY104343A (en) * 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
FR2636946B1 (fr) * 1988-09-23 1990-11-02 Lipha ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant
US5153206A (en) * 1988-12-02 1992-10-06 Pfizer Inc. Arylpiperidine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9202502A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534525B1 (en) 1995-12-22 2003-03-18 Warner-Lambert & Company 2-substituted piperidine analogs and their use as subtype-selective NMDA receptor antagonists

Also Published As

Publication number Publication date
TW267164B (fr) 1996-01-01
WO1992002502A1 (fr) 1992-02-20
MA22250A1 (fr) 1992-04-01
KR930701402A (ko) 1993-06-11
JPH06500093A (ja) 1994-01-06
AP279A (en) 1993-08-01
AU8327191A (en) 1992-03-02
NZ239268A (en) 1994-06-27
IL99073A0 (en) 1992-07-15
CA2088491A1 (fr) 1992-02-07
AP9100313A0 (en) 1991-10-31
PT98574A (pt) 1992-06-30
MX9100513A (es) 1992-04-01
CN1061963A (zh) 1992-06-17
IE912759A1 (en) 1992-02-12

Similar Documents

Publication Publication Date Title
EP0542846A1 (fr) Piperidines a substitution n-hydrocarbyle en position 4, leur preparation et leur utilisation comme agents de blocage du calcium
US4166119A (en) Analgesic and tranquilizing spiro[dihydrobenzofuran]piperidines and pyrrolidines
AP236A (en) "3-substituted piperdine derivatives, pharmaceutical compositions containing them and their use in therapy".
US4241071A (en) Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
EP0629190A1 (fr) Composes utilises comme antagonistes des canaux calciques
EP0339579B1 (fr) Composés de pipéridine et leur préparation et utilisation
US6677330B1 (en) Fluorides of 4-substituted piperidine derivatives
WO1994013291A1 (fr) Utilisation d'amines cycliques a substitution aryloxyalkyle comme antagonistes des canaux a calcium et nouveaux derives de piperidine phenyloxyalkyle
US7994198B2 (en) Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
WO1992022527A2 (fr) Derives de pyrrolidine 3-substitues comme antagonistes du calcium
EP1325912A1 (fr) Derives 2,2-diphenylbutanamide et agents pharmaceutiques contenant ces composes
WO1995024390A1 (fr) Nouvelles piperidines substituees par phenyl(-alkyl/alkoxy)-1-aminoalkyle et pyrolidines utilisees comme antagonistes des canaux calciques
US5227379A (en) Piperidine compounds and their preparation and use
EP0724577A1 (fr) Amines heterocycliques pour le traitement des acces ischemiques
US5158961A (en) Piperidine compounds and their preparation and use
WO1993022302A1 (fr) N-aryloxy(thio)alkyl-azacycloalcanes utiles en tant qu'antagonistes des canaux calciques
WO1995011240A1 (fr) Derives amines servant d'antagonistes des canaux a calcium
US5198451A (en) Heterocyclic carboxylic acids
EP0125315A1 (fr) Derives de phenoxyaminopropanol
WO1995033722A1 (fr) Piperidines, pyrrolidines, morpholines et tiopmorpholines a substitution phenoxyalcoyle en tant qu'antagonistes des canaux calciques
US4414219A (en) Antidepressant (α-phenyl-2-tolyl)azacycloalkanols and derivatives thereof
US4311703A (en) Antidepressant and tranquilizing (α-phenyl-2-tolyl)-azacycloalkenes
US5608069A (en) 1-substituted, 3-carboxylic acid piperidine derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19960213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960625